Zimmer Biomet Holdings, Inc. (NYSE: ZBH), commonly "Zimmer Biomet," is a publicly traded American medical-device manufacturer headquartered at 345 East Main Street, Warsaw, Indiana. The company traces its history to 1927, when Justin O. Zimmer founded Zimmer Manufacturing Company in Warsaw; the current Delaware-incorporated parent was spun off from its former parent in 2001 and took its present name after acquiring Biomet in 2015. It is an operating company, not a holding/NPE vehicle. Press and financial profiles put headcount at roughly 17,000 employees and FY2025 net sales at about $8.23 billion (FY2024: $7.68 billion).
Products / operations. Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants and related technologies. Its portfolio spans knee, hip, and shoulder reconstruction (e.g., Persona, NexGen, Vanguard, and Gender Solutions knee systems); sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; bone cement and surgical products; and integrated digital and robotic technologies, including its Signature Personalized Patient Care patient-specific instrumentation. It sells through direct channels and distributors across three regional segments: Americas; EMEA; and Asia Pacific. Its main customers are orthopedic surgeons, neurosurgeons, hospitals, and buying groups.
Patent-litigation posture. The tracked data show Zimmer Biomet on the plaintiff side in a single case (Zimmer US, Inc. et al. v. Conformis, Inc., filed 2019-11-05 in D. Del.) and zero cases as a defendant. That one-off plaintiff appearance reflects a defensive/declaratory response in an active dispute rather than an NPE-style assertion campaign; the company is an operating manufacturer, not a patent-assertion entity. The matter sits in the District of Delaware, a common venue for medical-device patent suits.
Context. External sources show Conformis, Inc. (Billerica, Mass.) sued Zimmer Biomet in D. Del. in August 2019 over patient-specific knee, hip, and shoulder instrumentation patents, alleging infringement by Zimmer's Signature, Persona, NexGen, Vanguard, and Gender Solutions systems. The parties settled in May 2020, dismissing all litigation, cross-licensing their respective patient-specific instrument and implant patents, with Zimmer paying Conformis $9.6 million.